Login / Signup

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.

Won Suk LeeDong Sung KimJeong Hun KimYoonki HeoHannah YangEun-Jin GoJin Hyoung KimSeung Joon LeeByung Cheol AhnJung Sun YumHong Jae ChonJoo Hoon Kim
Published in: Journal for immunotherapy of cancer (2022)
Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade.
Keyphrases
  • immune response
  • toll like receptor
  • dendritic cells
  • combination therapy
  • replacement therapy